Abstract
Background: The VELOUR randomized placebo-controlled phase III trial established aflibercept combined with FOLFIRI as an effective regimen in metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. Health-related quality of life (HRQoL) was not evaluated in VELOUR trial. Methods: The current study prospectively evaluated the impact on HRQoL (using the Functional Assessment of Cancer Therapy-Colorectal - FACT-C scale), the effectiveness, and tolerability of aflibercept plus FOLFIRI prescribed in Bulgarian patients with mCRC in daily clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
